We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+60.76%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$296M
AUM Growth
+$73.6M
(+33%)
Cap. Flow
+$40.9M
Cap. Flow
% of AUM
13.79%
Top 10 Holdings %
Top 10 Hldgs %
46.59%
Holding
90
New
21
Increased
29
Reduced
18
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$15M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$10.5M |
| 3 |
Krystal Biotech
KRYS
|
+$8.67M |
| 4 |
Biogen
BIIB
|
+$4.63M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$4.59M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
+$7.2M |
| 2 |
Nuvalent
NUVL
|
+$6.29M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$4.11M |
| 4 |
Pharvaris
PHVS
|
+$3.48M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$2.94M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $26.8M | 9.05% |
1,420,000
+1,270,000
| +847% | +$15M |
|
|
MRUS
2
DELISTED
Merus
MRUS
| $15.5M | 5.24% |
589,255
-79,529
| -12% | -$1.74M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.5M | 4.88% |
252,309
+200,625
| +388% | +$10.5M |
|
4
Schrodinger
SDGR
$1.23B
| $14.3M | 4.82% |
286,169
+73,344
| +34% | +$2.48M |
|
|
5
Krystal Biotech
KRYS
$9.78B
| $14M | 4.71% |
118,941
+84,927
| +250% | +$8.67M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.6M | 4.25% |
198,723
+73,688
| +59% | +$4.59M |
|
|
AKRO
7
DELISTED
Akero Therapeutics
AKRO
| $11.3M | 3.8% |
241,357
+38,796
| +19% | +$1.78M |
|
8
Oric Pharmaceuticals
ORIC
$1.11B
| $11.3M | 3.8% |
1,450,822
+14,877
| +1% | +$84.5K |
|
9
MoonLake Immunotherapeutics
MLTX
$1.64B
| $10.2M | 3.44% |
200,000
+94,250
| +89% | +$2.54M |
|
|
10
Biogen
BIIB
$28.1B
| $7.65M | 2.58% |
26,854
+15,543
| +137% | +$4.63M |
|
|
ETNB
11
DELISTED
89bio
ETNB
| $7.51M | 2.54% |
396,497
-41,718
| -10% | -$733K |
|
12
Cogent Biosciences
COGT
$6.57B
| $7.34M | 2.48% |
620,000
+40,736
| +7% | +$467K |
|
13
United Therapeutics
UTHR
$22.2B
| $6.63M | 2.24% |
30,029
+11,451
| +62% | +$2.54M |
|
14
MacroGenics
MGNX
$270M
| $6.5M | 2.2% |
1,215,675
-146,134
| -11% | -$901K |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| $6.48M | 2.19% |
720,508
-3,036
| -0.4% | -$28K |
|
16
Veracyte
VCYT
$4.67B
| $5.84M | 1.97% |
229,451
+19,798
| +9% | +$480K |
|
17
BioCryst Pharmaceuticals
BCRX
$2.41B
| $5.36M | 1.81% |
760,904
+183,147
| +32% | +$1.47M |
|
|
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
| $5.25M | 1.77% |
599,668
-68,254
| -10% | -$796K |
|
|
PSTX
19
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $5.18M | 1.75% |
2,945,948
+256,647
| +10% | +$656K |
|
|
20
Nuvalent
NUVL
$9.81B
| $4.85M | 1.64% |
115,067
-166,466
| -59% | -$6.29M |
|
21
Gilead Sciences
GILD
$162B
| $4.66M | 1.57% |
60,448
+318
| +0.5% | +$25.4K |
|
22
Vertex Pharmaceuticals
VRTX
$120B
| $4.64M | 1.57% |
13,175
-6
| -0% | -$2.02K |
|
23
TELA Bio
TELA
$37.1M
| $4.22M | 1.42% |
416,440
+362,344
| +670% | +$3.71M |
|
24
Viking Therapeutics
VKTX
$4.39B
| $4.19M | 1.42% |
258,595
-121,405
| -32% | -$2.54M |
|
25
Praxis Precision Medicines
PRAX
$8.98B
| $4M | 1.35% |
+231,744
| New | +$3.55M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA